What is fetal alcohol syndrome?
What causes fetal alcohol syndrome?
Who gets fetal alcohol syndrome?
How does alcohol cause disease?
What are the common findings?
How is fetal alcohol syndrome diagnosed?
How is fetal alcohol syndrome treated?
What are the complications?
How are the complications of fetal alcohol syndrome prevented?
What research is being done?
Links to additional information
by Randi Hagerman, M.D.
Professor of Pediatrics, University of Colorado Health Sciences Center
and The Children's Hospital
Fetal alcohol syndrome is a disorder caused by alcohol exposure in the womb. Alcohol
interferes with brain development in the fetus. It also causes unusual physical
features in the fetus, including facial structure abnormalities and bone growth
Alcohol is a "teratogen," meaning it causes birth defects. When a mother drinks
alcohol during her pregnancy, the alcohol in the bloodstream enters the fetal circulation
and interferes with cell growth and migration. This particularly affects early brain
development in the fetus. The growth of bones and organs, including the heart and
the kidneys, also can be significantly affected by alcohol exposure in the womb.
A fetus exposed to significant amounts of alcohol may be affected with fetal alcohol
syndrome; whereas, a fetus exposed to alcohol for limited times during pregnancy
may not be as severely affected or show evidence of fetal alcohol syndrome. Both
male and female fetuses can be affected.
The disorder affects individuals differently; some individuals have mild behavioral
problems or intellectual deficits, while other individuals have more severe complications
with bone and organ development. Exposure in the second and third trimester of pregnancy
usually leads to full fetal alcohol syndrome; however, exposure in the first trimester
may interfere with brain structure. Usually, if a mother stops drinking during the
first trimester of pregnancy, it is likely that the fetus will not be significantly
affected with fetal alcohol syndrome.
Alcohol interferes with the metabolism of cells, and it may cause early cell death
or lack of normal replication or migration.
Most children affected with full fetal alcohol syndrome have characteristic facial
abnormalities, including a small opening of the eye, underdevelopment of the mid-part
of the face, a thin upper lip, and a flat "philtrum" (the part of the face between
the upper lip and the bottom of the nose). In addition, individuals may have poor
growth of the mandible or the upper jaw. The base of the nose may be underdeveloped,
and the nose may be shorter than normal. Alcohol also may cause poor growth of the
head so that the head circumference is smaller than normal. In addition, these individuals
may have a short stature, and are usually thin.
Alcohol also causes dysfunction of the central nervous system, which may include
mental retardation or learning disabilities. Hyperactivity, with a short attention
span and poor impulse control, are very common. Depression, anxiety, and panic attacks,
along with psychotic thinking, including delusions or hallucinations, also are relatively
common, particularly in adolescence and adulthood.
Structural brain changes are not uncommon in individuals affected by fetal alcohol
syndrome. Poor development of the "corpus collosum," the band of fibers in the brain
that connects the left and the right side of the brain, is common. In addition,
the "cerebellum," an older area of the brain, may be underdeveloped. Rarely, other
more severe brain abnormalities may occur. A limited number of individuals with
fetal alcohol syndrome also may experience seizures, particularly in childhood.
Organs may be significantly affected by alcohol exposure in the womb, to include
Exposure to alcohol in the womb causes a wide range of abnormalities. The most severe
level is Fetal Alcohol Syndrome (FAS). FAS must have a confirmed history of maternal
alcohol exposure. For a full diagnosis of FAS, the patient must have the characteristic
facial abnormalities, in addition to growth retardation, i.e., a low birth weight
for gestational age or height/weight growth parameters less than the 10th percentile.
There also must be evidence of central nervous system neurodevelopmental abnormalities,
such as small head size, structural brain abnormalities, or neurological hard or
soft signs. Such signs include impaired fine motor skills, a sensory neural hearing
loss, poor tandem walking, or poor hand/eye coordination.
Individuals also may be diagnosed with Partial Fetal Alcohol Syndrome (PFAS). A
diagnosis of PFAS is confirmed by maternal alcohol exposure, in addition to some
of the characteristic facial features, growth retardation, central nervous system
neurodevelopmental abnormalities, or a complex pattern of behavioral or cognitive
Typically, these abnormalities are inconsistent with the child's development level,
and cannot be explained by family background or environment. These features can
include the following: learning difficulties; deficits in school performance; poor
impulse control; problems in social perception; deficits in higher level expressive
and receptive language development; poor capacity for abstraction; specific deficits
in mathematical skills; or problems in memory, attention, or judgment.
Another alcohol exposure disorder is Alcohol Related Birth Defects (ARBD). ARBD
requires the presence of congenital abnormalities, including malformations in the
cardiac system, the skeletal system, the kidney system, the eyes, or the auditory
The Alcohol Related Neurodevelopmental Disorder (ARND) requires central nervous
system neurodevelopmental abnormalities or a complex pattern of behavioral or cognitive
abnormalities, including learning disabilities and attention deficit problems. ARND
is the mildest form of fetal alcohol syndrome.
Usually, individuals have behavioral problems, such as hyperactivity or learning
disabilities, but do not show abnormal facial features, which are typical of alcohol
exposure. There is animal and human research indicating that abnormalities can occur
in the brain, leading to learning problems or behavioral difficulties, without having
abnormal facial features.
At the time of birth, newborns exposed to significant levels of alcohol may have
severe withdrawal symptoms. In approximately 33% of the cases, seizures may occur.
Medication, such as phenobarbital, can be given at the time of birth to control
the seizures; however, for many infants, medications are not necessary to treat
withdrawal symptoms. It is important to wrap the baby tightly, to dim the lights,
to reduce the noise level to avoid overstimulation, to feed the baby frequently,
and to massage the baby to help relaxation.
It is possible that the baby may have significant malformations at the time of birth,
such as a cleft lip or a cleft palate, and, occasionally, even a neural tube defect
can be related to alcohol exposure in the womb. The baby may have problems with
feeding and abdominal distention related to alcohol withdrawal. Help with oral feeding
may be obtained from an occupational therapist.
It also is important to treat the alcoholism of the mother. A treatment program-including
advocacy and psychological support for the mother, help with obtaining services
and entitlements, parent skills training, crisis intervention, guidance and feedback,
general encouragement, and a substance abuse program-is very beneficial.
Infants and preschoolers with fetal alcohol syndrome disorders should be enrolled
in a developmental program that has both language and motor therapy. Hyperactivity
and distractibility, which are associated with Attention Deficit Hyperactivity Disorder
(ADHD), often arises in preschool. Initially, behavioral techniques should be used
to control hyperactivity, both at home and at school. Tantrums and aggression also
may occur in preschool. If behavioral interventions are not adequate, then medication
may be helpful, even in preschool. Useful medications include clonidine (to decrease
hyperarousal) or stimulant medication, such as dextroamphetamine or methylphenidate.
There is some evidence that dextroamphetamine may be more effective than methylphenidate
for children with ADHD. Sleep disturbances also may occur, and the "Baby Go To Sleep
Tape" may be helpful. Medication, such as clonidine, can be used at bedtime. Melatonin,
which is the natural sleep hormone, also may be beneficial.
For the school-age child with a fetal alcohol syndrome disorder, deficits in language
and motor development also may continue, and may require individualized speech and
language therapy and occupational therapy. Some children overreact to stimuli or
have sensory motor integration problems. This can worsen hyperactive and tantrum
behavior, and should be treated by a sensory integration occupational therapy program.
Most children with fetal alcohol syndrome require special education support. A learning
disability teacher can use a multi-sensory approach for teaching academic skills,
such as reading or math.
Computers may enhance academic learning and language skills for children with fetal
alcohol syndrome. Computer programs may help with visual spatial perceptual skills.
Such programs as "KidPix," which enhances drawing and graphics, or "Blocks in Motion,"
which focuses on visual spatial processing, may be beneficial. Additionally, such
programs as "Oregon Trails," "Interactive Journeys," and "Where in the World is
Carmen Sandiego?" use problem solving skills through reading and listening cues,
and are helpful for academic progress in math and reading. Programs that enhance
writing skills, such as word prediction software, can expand written language abilities.
School-age children with fetal alcohol syndrome usually have problems with ADHD.
Stimulant medication, such as dextroamphetamine (Adderall and Dexedrine) or methylphenidate
(Ritalin), can be helpful in this age group.
Children who are affected by alcohol exposure in the womb should have a detailed
psychological assessment that documents their intellectual abilities or IQ, as well
as emotional difficulties. If significant emotional problems, such as anxiety, depression,
or mood swings occur, then ongoing counseling should be helpful. Sometimes, if significant
anxiety or depression exists, medication, such as Prozac or Zoloft, may be helpful.
If mood swings are a problem, then mood-stabilizing medication, such as Tegretol,
Depakote, or risperidone, can be helpful. Usually, medication to treat emotional
or behavioral problems work best when combined with counseling by a psychologist
or a mental health professional.
The main complications associated with FAS, PFAS, or ARND are the secondary disabilities
that are prominent in adolescence and adulthood. There is a high rate of mental
health problems, and 94% of individuals experience these difficulties. The combination
of mental health problems, in addition to a high rate of substance abuse, can lead
to legal problems.
In a large study of over 400 individuals with fetal alcohol syndrome disorders,
conducted in Seattle by Dr. Streissguth and her colleagues, it was found that 32%
of adolescents and 42% of adults were jailed for a crime. Alcohol problems also
occurred in 42% of adults. This high rate of social problems demands more intensive
intervention in childhood to avoid these secondary disabilities.
Individuals also may suffer from complications related to medications. For instance,
stimulant medications can decrease appetite and interfere with normal growth when
weight loss occurs. Careful monitoring of blood levels and liver function studies
are required with some of the mood stabilizers, because they may decrease the white
blood cell count or irritate the liver.
Careful medical follow-up, particularly when individuals are treated with medication,
is necessary. When taking medication, individuals should visit their doctor at least
two to three times a year.
The prevention of secondary disabilities is a more complicated issue, and it requires
intensive treatment from early childhood. Long-term counseling in adolescence and
early adulthood, in addition to more intensive vocational training with a job skill
trainer, is beneficial. Early education regarding the complications of drug and
alcohol use also is important. If these problems develop, an intensive substance
abuse program is necessary.
Research is being conducted regarding the prevention of fetal alcohol syndrome.
There is a massive public health program to educate women regarding the problems
associated with alcohol use when they are pregnant.
Very little research has been performed regarding the treatment of those individuals
who are affected by fetal alcohol syndrome. There is a great need for controlled
research regarding psychopharmacological interventions and educational interventions.
Animal research has suggested that cholinergic drugs may be beneficial for treating
hyperactivity and cognitive deficits; however, these, and other new drugs, have
not yet been studied in humans.
Research regarding innovative computer programs that enhance learning, such as the
"Fast Forward" program, using a computerized slowing of speech to improve auditory
processing deficits, may be helpful. However, these studies also have yet to be
National Organization of Fetal Alcohol Syndrome (NOFAS)
1819 H Street NW, Suite 750
Washington, DC 20006
Phone: (202) 785-4585
Fax: (202) 466-6456
Family Empowerment Network: Supporting Families Affected by Fetal Alcohol Syndrome and Effects
University of Wisconsin
519 Lowell Hall
610 Langdon Street
Madison, WI 53703
Phone: (800) 462-5254
Fax: (608) 262-6590
Fetal Alcohol Information Service
P.O. Box 95597
eattle, WA 98145-2597
National Association for Perinatal Addiction Research and Education (NAPARE)
11 E. Hubbard Street 200
Chicago, IL 60611
Fetal Alcohol Education Program
Boston University School of Medicine
1975 Maine Street
Concord, MA 01742
Phone: (978) 369-7713
FAS Family Resource Institute (FAS*FRI)
P.O. Box 2525
Lynnwood, WA 98036
Phone: (800) 999-3429
Fetal Alcohol and Drug Unit
University of Washington
180 Nickerson Street, Suite 309
Seattle, WA 98109
Phone: (206) 543-7155
National Clearing House for Alcohol and Drug Information (NCAID)
P.O. Box 2345
Rockville, MD 20852
Phone: (800) 729-6686
The "Baby Go To Sleep" tape may be obtained by calling (800) 537-7748.
Dorris, M. (1989) The Broken Cord. New York: Harper Collins.
Kleinfeld, J.K. and Wescott, S. (eds.) (1993) Fantastic Antone Succeeds! Experiences
in Educating Children with Fetal Alcohol Syndrome. Fairbanks: University of Alaska
Streissguth, A.P. and Kanter, J. (eds.) (1997) The Challenge of Fetal Alcohol Syndrome:
Overcoming Secondary Disabilities. Seattle: University of Washington Press.
Streissguth, A. (1997) Fetal Alcohol Syndrome: A Guide for Families and Communities.
Baltimore, MD: Paul H. Brooks Publishing.
Hagerman, R.J. (1999) Fetal Alcohol Syndrome. In: Neurodevelopmental Disorders:
Diagnosis and Treatment. New York: Oxford University Press.
About the Author
Dr. Hagerman received her M.D. from Stanford Medical School and completed her pediatric
residency at Stanford and at the University of California San Diego. She is now
a Professor of Pediatrics at the University of Colorado Health Sciences Center and
Co-Section Head of Developmental and Behavioral Pediatrics.
Her research interests are in Fragile X Syndrome, Fetal Alcohol Syndrome, organic
causes of ADHD and behavioral phenotypes.
Copyright 2012 Randi Hagerman, M.D., All Rights Reserved
The information contained in these topics is not intended nor implied to be a substitute for professional medical advice, it is provided for educational purposes only. You assume full responsibility for how you choose to use this information.
Always seek the advice of your physician or other qualified healthcare provider before starting any new treatment or discontinuing an existing treatment. Talk with your healthcare provider about any questions you may have regarding a medical condition. Nothing contained in these topics is intended to be used for medical diagnosis or treatment.
If you think that you are having a medical emergency,
call 911 or the number for the local emergency ambulance service NOW!
And when in doubt, call your doctor NOW
or go to the closest emergency department.
By using this website, you accept the information provided herein "AS IS." Neither RemedyConnect nor the providers of the information contained herein will have any liability to you arising out of your use of the information contained herein or make any express or implied warranty regarding the accuracy, content, completeness, reliability, or efficacy of the information contained within this website.
RemedyConnect, Inc. has created this privacy statement in order to demonstrate our firm commitment to your privacy. The following discloses our information gathering and dissemination practices for this website: http://www.remedyconnect.com.
Acquisition of Information through PMD
We do not acquire any more information about website visitors than is required by law or is otherwise necessary to provide a high level of service efficiently and securely. Our site's registration form requires users to give us contact information (e.g., their name and e-mail address) and demographic information (e.g., children's birth months, but not birth dates). We use customer contact information from the registration form to (1) send the user pertinent medical and parenting information and (2) allow your local health provider lists of who is registering on that provider's site as a parent/guardian, staff member, doctor, or visitor. Users may opt-out of receiving future mailings; see the choice/opt-out section below.
We use your IP address to help diagnose problems with our server and to administer our Website. Your IP address is used to help identify you and to gather broad demographic information.
Demographic and profile data is also collected at our site. We may use this data to tailor the visitor's experience at our site, showing them content that we think they might be interested in, and displaying the content according to their preferences.
Our site may use order forms to allow users to request information, products, and services.
Your Doctor's Right to Privacy
We will respect your doctor's right to privacy. A doctor typically does not give his/her e-mail address to the parents/guardians of patients. We will not provide the e-mail addresses of doctor(s) in the local practice to users of their site without the doctor(s)' permission. Their site is restricted to use by whomever they wish, and they may deny access to their site to one or more prior users. In unusual cases, doctors may change their private site's access code and arrange for us to e-mail the new access code to approved users.
This site contains links to other sites. RemedyConnect.com is not responsible for the privacy practices or the content of such Websites. See Disclaimers.
Disclosure to Third Parties
We will provide individually-identifiable information about website users to third parties only if we are compelled to do so by order of a duly-empowered governmental authority, we have the express permission of the visitor, or it is necessary to process transactions and provide you services from our affiliates: Live Agent Answering Service, Digital Answering Service, Medical Answering Service and Pediatric Answering Service.
Privacy and Our Business Partners
This site may make chat rooms, forums, message boards, and/or news groups available to its users. Please remember that any information that is disclosed in these areas becomes public information and you should exercise caution when deciding to disclose your personal information.
This site has security measures in place to protect the loss, misuse and alteration of the information under our control. For further information regarding our security, please contact us at email@example.com. If you have any concerns regarding the security of information, please do not provide any information to RemedyConnect, Inc. until you are comfortable with our security measures.
You may correct or update your User Registration information at any time, by visiting the User Registration section and providing your personal password that you set at registration. If need be, please email us at firstname.lastname@example.org.
Our site provides users the opportunity to opt-out of receiving e-mail communications from our partners or us, except communications approved by your doctor's practice office. To so opt-out, please email us at email@example.com. To be removed as a user, please email us at the same address. If need be, you may mail requests to us at RemedyConnect, Inc., 9200 E. Mineral Avenue, Suite 100, Centennial, CO 80112. Our telephone number is 303-793-0703.
Contacting the Website
If you have any questions about this privacy statement, the practices of this site, or your dealings with this Website, you can contact us by email at firstname.lastname@example.org or by mail at our address above.